Pfizers, Setback

Pfizer's Setback in Duchenne Muscular Dystrophy Treatment Trial Clears Path for Sarepta, and Many Other Pharma Companies | DelveInsight

Veröffentlicht: 07.08.2025 um 18:06 Uhr, prnewswire.co.uk

DelveInsight Business Research, LLP United States of America United Kingdom


+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pfizers-setback-in-duchenne-muscular-dystrophy-treatment-trial-clears-path-for-sarepta-and-many-other-pharma-companies--delveinsight-302173969.html

en | boerse | 67950101 |